Liza Vaezi

Oncology MSL, PharmD with focus on immune therapy,NSCLC, HNSCC, DTC, gyn onc and breast cancers.

[Raffaele Colombo @raffcolo]

#BehindThePaper 2/n

None of the approved ADCs (to date) is fully stable in circulation

There are 2 types of linker instabilities:
1) linker-drug instabilities, which release free drug
2) antibody-linker instabilities, which release the whole drug-linker

https://t.co/G7ovUvuB7B

[Paolo Tarantino @PTarantinoMD]

How do we build a new generation of safer and more active ADCs for treating cancer?

👉By understanding how they actually work (and stop working)

In this @CD_AACR review, we retrace 40 years of ADC development, highlighting key lessons learned.

🧵 below

https://t.co/p2Wafhwk8z

[Oren Gottfried, MD @OGdukeneurosurg]

Immune system one pager

[Paolo Tarantino @PTarantinoMD]

Why didn’t Dato-DXd improve OS in HR+/HER2- mBC, a setting were a different Trop2 ADC (SG) has previously shown OS advantage?

3 potential, non-exclusive explanations 👇

[Paolo Tarantino @PTarantinoMD]

Great recap of 2L+ data for HER2+ mBC with brain mets by @CristinaSaura3. mPFS >14 months with T-DXd across studies (vs 7.8 months with the tucatinib triplet). Supports an earlier use of T-DXd in this setting, though ILD remains a concern. #ESMOAmbassadors #ESMO24 @myESMO

[Guilherme Nader Marta @GuiNaderMarta]

DESTINY-Breast12, the largest prospective study of T-DXd in HER2+ mBC with brain metastases presented by @nlinmd shows 12-mo PFS of 61.6% & CNS PFS of 58.9% in BM cohort. CNS ORR: 79.2% (stable) & 62.3% (active). ILD/pneumonitis: 16.0% in BM, 12.9% in non-BM cohort
@OncoAlert

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Think you hear a lot about #ADCs now?

Just wait....here we go 🏎️!!!

107 topo1 ADCs in development currently to at least 39 diff 🎯

@AACRPres
#ESMO24
#ESMOAmbassadors

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

Dr. Viale discusses HER2 testing in #bcsm

📌HER-2 null only 12%

📍94% of those scored HER-2 low locally were confirmed centrally in DB-06 pop

🔆of those IHC 0 locally, centrally 40% ultra low and 24% low

💣 low is being missed in our communities

#ESMO24
#ESMOAmbassadors

[Abeid Athman (Omar). @bin_abeid]

Marleen Kok with very thoughtful discussion on the design of the KN522, : do all patients need adjuvant pembrolizumab; the irAEA especially in young women who would like to get pregnant. #ESMO2024 @OncoAlert @myESMO @kevinpunie @matteolambe @PTarantinoMD

[Hope Rugo @hoperugo]

Peter Schmid presents the OS data from KN522 #ESMO24 publl now in NEJM. >6 year FU: 9% EFS benefit, 5% ⬆️OS with pembro pre/post op for TNBC. Pts with PCR had 95% survival +/-pembro but 6% ⬆️OS in nonPCR + pembro. Safety same. Huge advance for TNBC. Need biomarkers! @OncoAlert

[Paolo Tarantino @PTarantinoMD]

Previously presented at #ASCO24 by @curijoey, the impressive results of DB06, testing T-DXd vs chemo for endocrine-refractory HR+ MBC, are now published in @NEJM.

Take home points ( 🧵 ):

https://t.co/DCqbNyjSgt

[Takahiro Matsuo (Taka), MD @TakaMatsuo_ID]

【Penicillin Allergy】@NEJM 2019

👉A very useful review for understanding the true mechanisms of penicillin allergy
👉A must-read at least once for everyone!

https://t.co/QGYGFkRdrR

#IDMedEd #IDFellow #Penicillin #Allergy

[Elisa Agostinetto @ElisaAgostinett]

At #ESMO24 @nlinmd presents data on T-DXd in Destiny-Breast12

T-DXd showed substantial overall and intracranial clinical activity in pts with HER2+ mBC 🧠

Median PFS 17.3 mos and CNS ORR 72% in pts with baseline brain mets

@OncoAlert

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Rates of pathologic complete response (pCR) after datopotamab deruxtecan
(Dato) in the neoadjuvant setting: Results from the I-SPY 2.2 trial
@MeghnaTrivedi3 #ESMO24 @OncoAlert #OncoAlertAF
• Highest pCR rate observed in Immune+ (79%) followed by TNBC (62%) subtypes
• > 50% of pCRs achieved by Block A alone and >90% achieved by Block B
• Ability to avoid taxane (Block B) and/or anthracycline (Block C) treatment
• In HR-/Immune-/DRD-, the modeled pCR rate for the treatment strategy outperformed the dynamic control
• pCR rates were higher in those who met preRCB criteria

[Arndt Vogel @ArndtVogel]

TACE +/- lenva + pembro for intermediate-stage HCC
#ESMO24
🔎Phs III LEAP-012
👉ORR 46 vs 33% (RECIST)
👉ORR 71 vs 49% (mRECIST)
👉mPFS 10 vs 14.6 mo
👉mOS not mature
👉AE ≥3 31% vs 71%
🧐strong ORR and PFS data, already practice-changing?
@myESMO #ESMOAmbassadors

[Paolo Tarantino @PTarantinoMD]

Impressive IC activity of T-DXd for HER2+ MBC in #DB12 presented by @nlinmd. mPFS=17 months, CNS-ORR =71.7%. Confirms the preferred 2L option for pts with HER2+ MBC. 9 G5 cases of ILD remind us of the importance of careful monitoring. Concomitant publication in @NatureMedicine!

[Erman Akkus @Erman_Akkus]

👑Presidential #ESMO24 -Practice changing trials @myESMO

➡️LEAP-012
Adding lenvatinib + pembro to TACE in intermediate-stage HCC

✅mPFS: 14.6 vs 10 mo; HR: 0.66, 95% CI: 0.51-0.84; P = 0.0002
➡️OS immature
❗️Grade 3-5 TRAEs: 71.3% vs 31.5%

@OncoAlert #cancer #oncology #MedX

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

DESTINY breast 12 @nlinmd #ESMO24
▪️ 12 month PFS overall, similiar w stable and active brain mets 62.9% & 59.6%
▪️ median PFS = 17.3 mon
▪️CNS ORR = 71.7%
▪️12-month OS was maintained in patients with BMs (90.3%) and without BMs (90.6%)

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 New treatment algorithm in the treatment of metastatic breast cancer in 2024
👉🏻Triple negative breast cancer❗️ now 🔛 By @curijoey 👏🏻 #ESMO24
@OncoAlert #OncoAlertAF

[Elisa Agostinetto @ElisaAgostinett]

At #ESMO24 @BarbaraPistill2 presents ICARUS-BREAST01, phase II study of patritumab deruxtecan (HER3-DXd) in HR+/HER2- advanced breast cancer

Clinically meaningful activity in pretreated patients (median 2 prior lines) with ORR 53.5%, and mPFS 9.4 mos

@OncoAlert